Gilead has announced today it has chosen Hoofddorp, a town few miles away from Amsterdam, as CAR-T center in Europe. The new facility will cover a 117,000 ft2 area and, once operational (2020), will employ a workforce of at least 300 people. The site will serve both as a developing and manufacturing center for cell therapies such as axicabtagene ciloleucel. The therapies to be developed in Hoofddorp were initially developed by Kite, acquired by Gilead last summer for $11.9bn. As for the US, Gilead has acquired the Santa Monica site from Astellas Pharma, in order to establish a new R&D and manufacturing center for cell therapies.